The patient-reported disease burden in adults with atopic dermatitis : a cross-sectional study in Europe and Canada
de Bruin-Weller, Marjolein (University Medical Center Utrecht)
Gadkari, Abhijit (Regeneron Pharmaceuticals. Inc)
Auziere, S. (Kantar - Health Division)
Simpson, E. L. (Oregon Health and Science University)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Barbarot, Sebastien (Centre Hospitalier Universitaire de Nantes)
Girolomoni, Giampiero (Universita di Verona)
Papp, K. (Probity Medical Research, Waterloo)
Pink, A. E. (St. John's Institute of Dermatology, Guy's and St. Thomas' NHS Foundation Trust and Kings College London)
Saba, G. (Kantar - Health Division)
Werfel, T. (Hannover Medical University)
Eckert, Laurent (Sanofi)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Cross-sectional data on patient burden in adults with atopic dermatitis () from real-world clinical practice are limited. This study compared patient-reported burden associated with adult across severity levels from clinical practices in Canada and Europe. This study included adults (18-65 years) diagnosed with by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37. 3%), moderate (n = 520; 35. 4%) or severe (n = 400; 27. 3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient-Oriented-Scoring of Atopic Dermatitis (PO-SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/. Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61. 2% vs. 50. 5%; P < 0. 001). Compared with moderate and mild, participants with severe had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0. 001). Mean ± score among participants with severe (16. 2 ± 6. 9) showed a large effect on quality of life that was higher than those with moderate (10. 2 ± 6. 3) and mild (5. 5 ± 4. 9) (both P < 0. 001). The burden among Cyclo and subgroups was generally similar to that of participants with severe . Adults with reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/ subgroups was similar to those with severe.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Journal of the European Academy of Dermatology and Venereology, Vol. 34 (january 2020) , p. 1026-1036, ISSN 1468-3083

DOI: 10.1111/jdv.16003
PMID: 31587373

11 p, 351.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats